Oligonucleotide Therapeutics and Delivery Conference 2020

SMi Group 16 - 17 September 2020, London, UK.
Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered "non-draggable". Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies.

SMi's inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical, biotechnology and academic institutions, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. From optimizing particle size to choosing the right nanocarrier systems, the conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. Discussions will be centered around improving targeted therapy uniting the field's biggest players to share their opinions.

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.

Benefits of attending

  • Gain first-hand insight into oligonucleotide therapy clinical success up to date for improving development of novel agents in your pipeline
  • Listen to case studies presenting the latest candidates undergoing pre-clinical and clinical research
  • Deepen your understanding of crucial delivery methods and available platforms for non-hepatocytic delivery
  • Collaborate with members of the oligonucleotide community leading pharmaceutical, biotechnology and academic representatives to maximise future opportunities

Plus, an interactive half day pre-conference workshop on Oligonucleotide drug discovery: Target selection, delivery, molecular design and lead identification.

Chair for 2020

  • Nagy Habib, Head of HBP Surgery, Imperial College London and Co-Founder, Head CNN of R&D and Chief Medical Officer, Mina Therapeutics

Scientific Advisory Board 2020

  • Ekkehard Leberer, Senior Director, Alliance Management, Sanofi
  • Mark Edbrooke, Independent Consultant
  • Troels Koch, Chief Technology Officer, SVP Science and Technology, Inexos Therapeutics
  • Sudhir Agrawal, Founder and President, ARNAY Sciences and Idera Pharma and Professor, University of Massachusetts Medical School

Featured 2020 speakers include

  • David Evans,Chief Scientific Officer, Sirnaomics
  • Alexey Wolfson, CEO, Advirna
  • Stefan Vonhoff, VP Chemistry & Manufacturing, NOXXON Pharma
  • Vera Brinks, Director Pharmaceutics, ProQR Therapeutics
  • Matthew Catley, Research Director, MiNa Therapeutics
  • Steve Pascolo, Founder and CEO, Miescher Pharma

Who should attend

  • RNA Biology/Discovery
  • Novel Therapeutic Modalities
  • Innovation Technologies
  • C-level Scientific Executives
  • Formulation and Drug Delivery
  • Clinical Research and Development
  • Cell Biology

Early-bird rates

  • Book by April and save £600
  • Book by 29th May and save £300
  • Book by 30th June and save £200

For further information and to register, please visit:
http://www.oligonucleotide.co.uk/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Positive new data for Johnson & Johnson single…

Johnson & Johnson (NYSE: JNJ) (the Company) announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly sp...

GSK and Alector announce global collaboration in i…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Alector (Nasdaq: ALEC), today announced a strategic global collaboration for the development and commercialisation of two clinical...

Tezepelumab granted Priority Review by U.S. FDA

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelu...

One shot of the Sputnik V vaccine triggers strong …

A single dose of the Sputnik V vaccine may elicit significant antibody responses against SARS-CoV-2, finds a study published July 13 in the journal Cell Reports Medicine...

Are silver nanoparticles a silver bullet against m…

Antimicrobials are used to kill or slow the growth of bacteria, viruses and other microorganisms. They can be in the form of antibiotics, used to treat bodily infections...

"Long COVID": More than a quarter of COV…

In a new study of adults from the general population who were infected with COVID-19 in 2020, more than a quarter report not having fully recovered after six to eight mon...

mRNA vaccines slash risk of COVID-19 infection by …

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of ...

Cancer cells eat themselves to survive

It is the membrane of cancer cells that is at the focus of the new research now showing a completely new way in which cancer cells can repair the damage that can otherwis...

U.S. FDA grants Priority Review for the Biologics …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) granted Priority Review designation for the Biologics Li...

Collaboration between AbbVie, Biogen and Pfizer cr…

The access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequenc...

Artificial intelligence could be new blueprint for…

Writing in the July 12, 2021 online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses...

Anti-tumor agent from the intestine

It is believed to be involved in the development of chronic inflammatory intestinal diseases, to trigger diabetes, to be responsible for obesity, even neurological diseas...